Sacubitril/Valsartan

Senior Leader Additions Deepen Excellence in Strategy and CreativeNEW YORK, Dec. 3, 2024 /PRNewswire/ -- Imre welcomes two new leaders reinforcing its Strategy and Creative functions as it continues to focus on deepening its healthcare agency-of-record engagements. Haifa Barbari joins in the new role of Executive Vice President of Strategy and Customer Experience, along with Senior Vice President, Group Creative Director of Copy, Joe Macera. Continue Reading Imre Welcomes Haifa Barbari and Joe Macera, Reinforcing the Agency’s Momentum as Healthcare AOR of Choice "We're excited to welcome Haifa and Joe to the Imre team," said Anna Kotis, President. "Haifa's strategic expertise in global healthcare and her drive for innovation align perfectly with our mission to deliver impactful, future-focused solutions. Joe's proven creative leadership in launching major health campaigns strengthens our ability to craft resonant narratives for both healthcare professionals and patients. These two leaders will be instrumental in advancing the work we do for our client partners." Haifa Barbari, an award-winning strategist and futurist with 18 years of global experience, specializes in health, tech, and emerging markets. She has worked across the UK, US, and Asia-Pacific with pharma, health tech, startups, and nonprofits, creating unified brand and customer experience strategies. Passionate about solving business problems, Haifa thrives in uncertain environments and is eager to collaborate on innovative solutions. As EVP of Strategy and Customer Experience at Imre, she will lead and enhance the agency's strategic offerings connecting behavior change with the impact of AI. She'll co-create how we bring mutual meaning and value to our clients and the rising empowered patient and HCP, and build programs and services that impact healthcare, one brand and experience at a time. "We're living through unprecedented change, and I'm excited to join Imre at this pivotal time to bring my expertise in health, tech, and emerging trends, to strategically partner with our clients, and guide how to win in market now, and future proof their business," said Barbari. "I'm excited to partner with the team to reimagine creative and engagement approaches, driving progress for our clients in an ever-evolving world."Additionally, Joe Macera joins the agency with more than 12 years of healthcare advertising experience. Through his career, Macera has crafted impactful campaigns across oncology, cardiology, CNS, and infectious diseases, leading major launches for brands such as Pfizer's Elrexfio, Novartis' Entresto, and Sanofi/Regeneron's Praluent. At Imre, he will leverage his experience to tackle challenges with innovative solutions and guide creative strategy."I'm honored to join Imre and collaborate with a team of leaders I greatly admire," said Macera. "It's exciting to be part of an agency driven by shared values and a clear vision. I look forward to supporting our creative team, fostering inclusivity, and helping expand our portfolio of healthcare AOR experience, creating meaningful work that impacts healthcare professionals and patients." About Imre: Imre is a brand engagement agency that reaches people at pivotal moments through modern communications, new technologies and cutting-edge creativity. Imre works with many of the world's leading companies and high-growth brands. Driven by innovation and rooted in earned and social media, the agency's integrated suite of marketing communications services includes brand strategy, creative, omnichannel marketing, modern earned and paid media and data and analytics. Imre partners with a diversified and growing portfolio of healthcare and consumer organizations. The agency maintains offices in New York, Baltimore, and Philadelphia in addition to a group of employees who work from anywhere. Imre is an LGBTQ-founded company. SOURCE imre WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed to Endpoints News on Thursday. And Novartis is not done yet. It is still on the lookout for bolt-on M&A opportunities — but don’t expect them to go higher than $3 billion. “That’s not that we couldn’t do a little bit bigger, but that’s the majority of the available target companies, if you will,” Novartis CFO Harry Kirsch told the media ahead of its investor event in London on Thursday. CEO Vas Narasimhan added that a lot of M&A from the recent past has been in the $1 billion to $2 billion range, pointing to its acquisitions of Mariana Oncology and KateTx. Over the past eight years, it made $5 billion to $10 billion deals only “occasionally” because of valuation considerations and “financial discipline,” he added. Novartis will take on KateTx’s pipeline of preclinical candidates in Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. The San Diego biotech’s gene therapy tech features adeno-associated virus capsids that deliver their payloads into specific tissues to avoid off-target issues such as hepatic side effects. In June 2023, it said that it was partnering with Astellas on a neuromuscular disease called X-linked myotubular myopathy. Novartis revealed its purchase of KateTx ahead of its Meet Novartis Management event in London that was intended to reassure investors its pure-play strategy is bearing fruit now and in the next several years. A key part of its growth strategy is more M&A as “replacement power,” with the company facing the loss of exclusivity for key drugs such as Entresto , Kirsch said. When asked if changes to the Federal Trade Commission could lead to Novartis raising its M&A budget, Narasimhan said the FTC is not a major driver of its decisions. As a part of its reorg, the company zeroed in on four therapeutic spaces: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. “Preclinical, Phase 1, Phase 2 area — that’s the opportunity where we can step in” and Novartis can add value to the acquired company, Narasimhan said, adding that it’s challenging to “find synergies, harder to justify” with later-stage candidates. Narasimhan said that when it bought MorphoSys for $2.9 billion, its lead oncology candidate , pelabresib, was in an ongoing Phase 3 trial. “We saw the opportunity in an area of myelofibrosis that we’ve been in for a long period of time, and we took a bet on an ongoing clinical trial,” he said, adding that if it had waited for the late-stage readout, the purchase price would have been “double at least.” But that bet on MorphoSys led to the company taking an $800 million impairment hit just months after the deal closed due to emergent malignancies. “In this case, it didn’t go our way,” he said, nonetheless noting the company’s overall M&A track record . As for pelabresib, the company’s next update should come in the second half of next year. Narasimhan said it is monitoring patients until the middle of next year. “We are also planning to conduct additional studies to look at certain subpopulations of myelofibrosis patients where pelabresib could have a better benefit-risk profile. So I think all of that will take us at least until 2027 — it might take longer, depending on the safety topic,“ he added.